We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current HALO market cap is 6.66B. The company's latest EPS is USD 3.6040 and P/E is 14.99.
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 195.88M | 231.35M | 290.08M | 298.01M | 264.86M |
| Operating Income | 95.54M | 117.24M | 163.2M | 175.5M | 141.54M |
| Net Income | 76.82M | 93.25M | 137.01M | 137.01M | 118.1M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 267.59M | 443.31M | 660.12M | 829.25M | 1.02B |
| Operating Income | 144.26M | 275.9M | 267.53M | 337.57M | 551.48M |
| Net Income | 129.09M | 402.71M | 202.13M | 281.59M | 444.09M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.84B | 1.97B | 2.12B | 2.06B | 2.2B |
| Total Liabilities | 1.66B | 1.68B | 1.67B | 1.7B | 1.71B |
| Total Equity | 177.81M | 289.42M | 452.7M | 363.82M | 482.27M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 579.92M | 1.1B | 1.84B | 1.73B | 2.06B |
| Total Liabilities | 428.88M | 907.48M | 1.67B | 1.65B | 1.7B |
| Total Equity | 151.05M | 196.95M | 169.8M | 83.81M | 363.82M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 129.43M | 185.22M | 300.6M | 479.06M | 154.22M |
| Investing | -82.68M | -124.72M | -292.2M | -262.72M | -90.42M |
| Financing | -489k | 8.99M | 27.55M | -218.86M | -3.32M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 55.45M | 299.44M | 240.11M | 388.57M | 479.06M |
| Investing | 78.35M | -406.29M | -487.01M | -96.91M | -262.72M |
| Financing | -106.28M | 77.87M | 362.37M | -407.99M | -218.86M |
| Market Cap | 6.66B |
| Price to Earnings Ratio | 14.99 |
| Price to Sales Ratio | 6.56 |
| Price to Cash Ratio | 57.46 |
| Price to Book Ratio | 18.3 |
| Dividend Yield | - |
| Shares Outstanding | 123.22M |
| Average Volume (1 week) | 1.42M |
| Average Volume (1 Month) | 1.9M |
| 52 Week Change | 9.57% |
| 52 Week High | 70.505 |
| 52 Week Low | 42.01 |
| Spread (Intraday) | 0.53 (0.98%) |
| Company Name | Halozyme Therapeutics Incorporated |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.halozyme.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
